Active Ingredient History
Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Glaucoma, Angle-Closure (approved 2010)
Glaucoma, Open-Angle (approved 2010)
Head and Neck Neoplasms (approved 1994)
Ocular Hypertension (approved 2010)
Sjogren's Syndrome (approved 1994)
Anisocoria (Phase 4)
Breast Neoplasms (Phase 3)
Conjunctivitis (Phase 2)
Dry Eye Syndromes (Phase 3)
Glaucoma (Phase 3)
Glaucoma, Angle-Closure (Phase 4)
Glaucoma, Open-Angle (Phase 4)
Head and Neck Neoplasms (Phase 3)
Healthy Volunteers (Phase 1)
Mouth (Phase 3)
Neoplasms (Phase 3)
Ocular Hypertension (Phase 4)
Presbyopia (Phase 4)
Pseudophakia (Phase 3)
Quality of Life (Phase 3)
Sjogren's Syndrome (Phase 4)
Urinary Bladder, Overactive (Phase 3)
Urinary Incontinence (Phase 1)
Vaginal Diseases (Phase 3)
Vision, Low (Early Phase 1)
Xerostomia (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
